AstraZeneca Korea announced on April 1 that it has appointed Ohad Goldberg, currently CEO of AstraZeneca Israel, as the new CEO of AstraZeneca Korea, effective May 1.


Ohad Goldberg, newly appointed CEO of AstraZeneca Korea. AstraZeneca Korea.

Ohad Goldberg, newly appointed CEO of AstraZeneca Korea. AstraZeneca Korea.

View original image

Goldberg brings over 20 years of international leadership experience in the fields of life sciences, biotechnology, and agricultural technology (Ag-Tech), with proven expertise in commercial operations, market access, and external affairs. He has served in senior global and regional leadership roles, including as global launch leader for respiratory biologics, head of market access and head of the respiratory business in Israel, and as leader of commercial strategy for the European region.


Previously, as CEO of AstraZeneca Israel, Goldberg was recognized for spearheading external partnerships with government, healthcare stakeholders, academia, and innovation platforms. He has also represented the company in various leadership capacities, including as Chairman of the Board of AION Labs and as a board member of Pharma Israel, the association of multinational pharmaceutical companies in Israel.



Goldberg stated, "It is truly an honor to take on this role at a pivotal moment for healthcare reform in Korea. I look forward to working with AstraZeneca Korea’s talented team to contribute to the advancement of healthcare policy and to create sustainable, long-term value for Korean patients and society by expanding equitable access to innovative medicines."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing